Granules India gets USFDA approval for ANDA; stock surges
Granules India gets USFDA approval for ANDA; stock surges

Granules India gets USFDA approval for ANDA; stock surges

Apurva Joshi Article rating: 4.7

Granules India has received US Food & Drug Administration (USFDA) approval for abbreviated new drug application (ANDA), Trospium Chloride extended-release capsules, 60 mg.

Ten stocks close to their 52-week low
Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

DSIJ Intelligence Article rating: 3.6

The market opened in the red on April 24, 2020. The previous trading session witnessed the Sensex going up by 1.54 percent to end at 31,863 and the Nifty was up 1.4 percent to close at 9,313.

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

DSIJ Intelligence Article rating: 4.3

The market opened in the red on April 24, 2020. The previous trading session witnessed the Sensex going up by 1.54 percent to end at 31,863 and the Nifty was up 1.4 percent to close at 9,313.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 4.6

The market opened in the red on April 24, 2020, overall volumes in futures & options currently stand at 4,31 crore contracts with a turnover of Rs. 21,07,936.09 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 4.5

The market opened in the red on April 24, 2020, overall volumes in futures & options currently stand at 4,31 crore contracts with a turnover of Rs. 21,07,936.09 crore.

Larsen & Toubro receives order from DFCCIL
Larsen & Toubro receives order from DFCCIL

Larsen & Toubro receives order from DFCCIL

Amir Shaikh Article rating: 3.9

Railways Strategic Business Unit of L&T Construction’s Transportation Infrastructure IC in consortium with Kyosan Electric Manufacturing Co Ltd (Japan) has received a significant order in the form of three packages from Dedicated Freight Corridor Corporation of India Limited

Shilpa Medicare launches generic anticancer drug Dasatinib
Shilpa Medicare launches generic anticancer drug Dasatinib

Shilpa Medicare launches generic anticancer drug Dasatinib

Apurva Joshi Article rating: 3.5

Shilpa Medicare Limited has informed the bourses that it has launched Indian branded generic of Dasatinib, an anticancer drug with a brand name ‘Dasashil’. The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on April 12, 2020.

‘MCap to sales ratio gives valuation comfort
‘MCap to sales ratio gives valuation comfort

‘MCap to sales ratio gives valuation comfort

Pratik Shastri Article rating: 3.4

Further, the data also shows that FMCG companies trade at a much higher valuation than that of their sales. Like, Hindustan Unilever, Dabur India and Emami get up to eight times more valuations in comparison to their sales.

Soft start in offing
Soft start in offing

Soft start in offing

DSIJ Intelligence Article rating: 4.5

Indian markets might witness a soft start but an important event of the day is that Prime Minister Narendra Modi is likely to meet Finance Minister Nirmala Sitharaman to finalise a second stimulus package. The market participants will be all eyes & ears to this event as it could dictate the future trend of the market.

RSS
First28332834283528362838284028412842Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR